H1B Report
Side-by-side comparison

GlaxoSmithKline LLC vs Microsoft Corporation

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
GlaxoSmithKline LLC
PARank #FEIN 23-1099050
Entity B
Microsoft Corporation
WARank #5FEIN 91-1144442

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricGlaxoSmithKline LLCMicrosoft Corporation
Total filings73372,912
Certified %83.22%94.30%
Denied %0.41%0.15%
Withdrawn %2.05%0.69%
Cert-withdrawn %14.32%4.85%
Rank#5
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePAWA

Outcomes — GlaxoSmithKline LLC

DOL case-status mix.

Outcome breakdown: Certified 83.2%, Cert-withdrawn 14.3%, Withdrawn 2.1%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified83.2%
Cert-withdrawn14.3%
Withdrawn2.1%
Denied0.4%
Certified83.2%
Cert-withdrawn14.3%
Withdrawn2.1%
Denied0.4%

Outcomes — Microsoft Corporation

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 4.9%, Withdrawn 0.7%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

GlaxoSmithKline LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201023
FY201135
FY201248
FY201330
FY201424
FY201547
FY201660
FY201754
FY201855
FY201986
FY202031
FY202140
FY202217
FY202338
FY202459
FY202550
FY202636
Microsoft Corporation
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20104,407
FY20114,184
FY20124,005
FY20133,832
FY20143,674
FY20154,476
FY20164,919
FY20174,884
FY20185,457
FY20196,000
FY202051
FY2021110
FY2022150
FY20232,791
FY20249,492
FY20259,362
FY20265,118

Top 5 occupations — GlaxoSmithKline LLC

Top 5 occupations — Microsoft Corporation

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.